Skip to content

NAD+ for Hearing Loss & Tinnitus: What the Evidence Shows

A small hospital trial of intramuscular NAD+ reported better sudden-hearing-loss outcomes. Review the 45-patient design, limitations and tinnitus claims.

By Marcus HaleLongevity Research Editor
Updated

5 min read · 8 sources

On this page

Hearing is one of the newer frontiers for NAD+ marketing — you'll find NAD+ IV drips and NMN capsules pitched for "hearing protection," tinnitus, and "ear longevity." And unlike most such claims, this one isn't pure invention: there's a real, recent randomized human trial, plus a decade of animal work showing NAD+ precursors protect the inner ear. But the honest version separates a specific, supervised use in sudden hearing loss — where the human data are genuinely encouraging — from the much weaker, animal-only case for taking an NMN capsule to prevent age-related or noise-induced hearing loss. Here's exactly where the evidence is, and where it runs out.

Why the inner ear is an NAD+ story

Affiliate partner

Peter MD

Physician-prescribed injectable NAD+, sold as a course rather than a monthly plan

See Peter MD

The cochlea — the snail-shaped organ that turns sound into nerve signals — is metabolically ferocious. Its sensory hair cells and the spiral-ganglion neurons that carry their signal to the brain are mitochondria-dense and burn through energy continuously, which makes them critically dependent on NAD+, the central coenzyme of mitochondrial energy production. When the cochlea is stressed — by loud noise, by aging, by ototoxic drugs — NAD+-dependent repair and the protective NAD+-fueled enzymes (the sirtuins, especially SIRT3) become rate-limiting. That's the mechanistic rationale for asking whether boosting NAD+ can protect hearing, and reviews of NAD+ in aging place the inner ear squarely inside the broader NAD+-decline story 8.

Why the cochlea is an NAD+ story

Cochlear hair cells & nerve

Mitochondria-rich; depend on NAD+

Noise / aging / ototoxic drugs

Stress the cochlea, deplete NAD+

Less NAD+ → weaker SIRT3 defense

Loss of protective sirtuin activity

NAD+ precursors restore protection

Preserved hearing in mice → tested in humans

A coherent mechanistic chain — but the protection step was demonstrated mainly in mouse cochleae.

The 2026 human trial: real, encouraging — and narrow

The headline development is the first randomized, double-blind controlled trial of NAD+ in sudden sensorineural hearing loss (SSNHL) — the medical emergency where hearing drops abruptly, usually in one ear, over hours to days. The full report describes 45 patients randomized, with 38 completing follow-up: 18 in the NAD+ group and 20 controls. The intervention was 5 mg of NAD+ by daily intramuscular injection during inpatient care, added to a multi-drug hospital protocol. Controls received the hospital protocol without a matched NAD+ injection 1.

The results were striking. The NAD+ group recovered substantially more hearing — about a 40 dB improvement in pure-tone average versus roughly 23 dB in the control group (p = 0.010) — and a far higher share met the criteria for an "effective" recovery (about 94% vs 60%, p = 0.003) 1. The paper also reports a shorter estimated time to complete recovery; that survival-analysis estimate should not be read as a directly observed median for every patient. Tinnitus and ear fullness were secondary outcomes 1.

Hearing & tinnitus claims readout

  • NAD+ → recovery in sudden sensorineural hearing lossWeak evidence

    45 randomized, 38 completers; 5 mg IM plus hospital care. Larger hearing-threshold change; no matched NAD+ placebo injection. Needs replication.

  • NAD+ precursors → noise / age / ototoxic protection (ANIMAL)Strong evidence

    Multiple consistent mouse studies (NR + SIRT3, ribbon synapses, aging cochlea). Strong as preclinical evidence only.

  • NMN / NAD+ → preventing everyday hearing loss in peopleNone evidence

    No human prevention trial. Raising blood NAD+ is not the same as protecting the cochlea.

  • NAD+ / NMN → standalone chronic tinnitusNone evidence

    Only human tinnitus signal is secondary, inside the sudden-hearing-loss trial. No dedicated tinnitus trial.

Evidence judged on human randomized outcomes. The small human signal concerns an intramuscular hospital protocol for sudden loss, with design and attrition limits. Prevention remains unproven.

The authors describe the trial as double-blind, but the comparison was standard treatment rather than a matched placebo injection. The favorable result is preliminary, with important limits:

  • It is small and lost participants after randomization. Seven of 45 randomized people did not complete follow-up. Replication and a more robust analysis are needed.
  • It's a specific condition. This was sudden sensorineural hearing loss — a treat-it-fast emergency — added on top of standard therapy (typically steroids). It is not evidence that NAD+ helps long-standing hearing loss, age-related decline, or chronic tinnitus.
  • The route and care setting matter. This was a 5 mg intramuscular hospital protocol, not evidence for a commercial IV drip, home injection program or oral supplement.

So the accurate read: in sudden hearing loss, NAD+ as an adjunct under medical care showed a real and sizable benefit in one small RCT — promising enough to warrant bigger trials, not yet proof for routine use, and absolutely not a reason to delay urgent treatment.

The animal case: noise, aging, and ototoxic drugs

Behind that human trial sits a decade of consistent preclinical work — and it's worth understanding because it's both the strongest part of the mechanistic story and the part the marketing most often overstates as if it were human-proven.

The landmark study, published in Cell Metabolism in 2014, showed that the NAD+ precursor nicotinamide riboside (NR) activated SIRT3 and protected mice from noise-induced hearing loss — preventing the loss of the cochlear nerve connections (ribbon synapses) that noise destroys 2. Independent work confirmed that NR protects against noise damage by preserving those same hair-cell ribbon synapses 3. For age-related hearing loss, long-term NAD+ supplementation slowed the progression of hearing decline in aging mice 4. And for drug-induced (ototoxic) hearing loss, a reduced form of NR protected the cochlea against aminoglycoside antibiotic damage via SIRT1 5, while a 2026 study found another NAD+ precursor attenuated age-related hearing loss by suppressing cochlear cell death and senescence through SIRT3 6.

That is an unusually coherent body of preclinical evidence — multiple labs, multiple insults (noise, age, drugs), consistent protection, plausible mechanism. But every one of those studies is in mice or cell models. None shows that a person taking NMN or NR prevents their own noise-induced or age-related hearing loss. NAD+ precursors do reliably raise NAD+ in humans — oral NR is orally bioavailable and boosts blood NAD+ in people 7 — but raising blood NAD+ is not the same as protecting the cochlea, which the human data have not demonstrated for prevention.

Where the marketing outruns the evidence

Put the pieces together and the honest map looks like this:

  • Sudden sensorineural hearing loss: one small double-blind RCT showing real benefit from NAD+ as a supervised adjunct 1. Promising, needs replication, must not delay standard emergency care.
  • Noise-induced, age-related, and ototoxic hearing loss: strong, consistent animal evidence that NAD+ precursors protect the cochlea 23456 — but no human prevention trial.
  • Chronic tinnitus on its own: the only human tinnitus signal is the secondary improvement seen inside the SSNHL trial 1. There is no dedicated human trial of NAD+ or NMN for standalone chronic tinnitus.

So claims that an NMN capsule or NAD+ drip will "protect your hearing," "cure tinnitus," or "reverse age-related hearing loss" are extrapolation from rodent cochleae — exactly the kind of leap that often fails to translate. The one place the human data are real is narrow, urgent, and clinically supervised.

Bottom line

A small hospital trial, published online in 2025 and in a 2026 issue, reported that NAD+ added to hospital care produced a larger change in the hearing-threshold measure in sudden sensorineural hearing loss and improved tinnitus and aural fullness 1. It analyzed 38 of 45 randomized patients and used an intramuscular adjunct in a specific hospital setting. For everyday hearing protection, age-related decline, and chronic tinnitus, the supportive data remain animal-only 23456, and there's no human trial that taking NMN or NAD+ prevents hearing loss. Treat NAD+ for hearing as a promising research direction — and, if your hearing drops suddenly, see an ENT urgently rather than reaching for a supplement. For the broader picture, see our pillar guide to NAD+ therapy, and because the human signal here came from delivered NAD+ rather than a capsule, our honest looks at NAD+ IV therapy and NAD+ injections, plus where products land overall in the best NAD+ supplements.

This is consumer education, not medical advice. Sudden hearing loss is a medical emergency — see an ENT specialist immediately. Do not use supplements in place of evaluation for any hearing change or tinnitus.

Frequently asked questions

Is there real evidence NAD+ helps hearing loss?

For one specific condition, yes. A small trial published in a 2026 issue, with 45 randomized and 38 completing follow-up found that adding intramuscular NAD+ to hospital treatment for sudden sensorineural hearing loss produced a larger hearing-threshold change (about 40 dB vs 23 dB among 38 completers) and improved tinnitus and ear fullness, with faster recovery. That's a genuine, encouraging result — but it's one small trial, in a specific emergency condition, used under medical care. It is not evidence that NAD+ helps long-standing or age-related hearing loss.

Can NMN or NAD+ supplements prevent hearing loss?

Not proven in humans. The evidence that NAD+ precursors protect against noise-induced, age-related, and drug-induced hearing loss is strong but entirely from mice and cell models. No human trial shows that taking NMN or NR prevents your own hearing loss. These compounds do raise blood NAD+ in people, but that's not the same as protecting the cochlea.

Does NAD+ help tinnitus?

The only human signal is indirect. In the sudden-hearing-loss trial, tinnitus and aural fullness improved more in the NAD+ group as a secondary outcome. But there is no dedicated human trial of NAD+ or NMN for standalone chronic tinnitus, so it remains unproven for tinnitus on its own.

I think my hearing just dropped suddenly — should I take an NAD+ supplement?

No — see an ENT immediately. Sudden hearing loss is a medical emergency where treatment timing matters enormously, and standard care (usually steroids) works best when started fast. Even in the positive trial, NAD+ was given as an adjunct on top of that standard care, not instead of it. Reaching for a supplement instead of urgent evaluation could cost you permanent hearing.

Is the animal evidence for NAD+ and hearing strong?

As preclinical evidence, yes — and unusually consistent. Multiple labs have shown that NAD+ precursors like nicotinamide riboside protect mouse cochleae from noise damage (via SIRT3 and by preserving nerve-cell ribbon synapses), slow age-related hearing decline, and guard against ototoxic-drug damage. But consistent mouse data is a reason to run human trials, not proof of benefit in people.

References

  1. Gao M, Guan Y, Yue X, et al. (2026). NAD+ Enhanced on Hearing Recovery in Sudden Sensorineural Hearing Loss: Randomized Controlled Trial. The Laryngoscope. https://pubmed.ncbi.nlm.nih.gov/41035311/
  2. Brown KD, Maqsood S, Huang JY, et al. (2014). Activation of SIRT3 by the NAD+ precursor nicotinamide riboside protects from noise-induced hearing loss. Cell Metabolism. https://pubmed.ncbi.nlm.nih.gov/25470550/
  3. Han S, Du Z, Liu K, Gong S (2020). Nicotinamide riboside protects noise-induced hearing loss by recovering the hair cell ribbon synapses. Neuroscience Letters. https://pubmed.ncbi.nlm.nih.gov/32171805/
  4. Okur MN, Sahbaz BD, Kimura R, et al. (2023). Long-term NAD+ supplementation prevents the progression of age-related hearing loss in mice. Aging Cell. https://pubmed.ncbi.nlm.nih.gov/37395319/
  5. Fang J, et al. (2022). A reduced form of nicotinamide riboside protects the cochlea against aminoglycoside-induced ototoxicity by SIRT1 activation. Biomedicine & Pharmacotherapy. https://pubmed.ncbi.nlm.nih.gov/35658237/
  6. Yuan C, et al. (2026). NRH attenuates age-related hearing loss by suppressing cochlear ferroptosis and cellular senescence via Sirt3 activation. Free Radical Biology and Medicine. https://pubmed.ncbi.nlm.nih.gov/41759794/
  7. Trammell SAJ, Schmidt MS, Weidemann BJ, et al. (2016). Nicotinamide riboside is uniquely and orally bioavailable in mice and humans. Nature Communications. https://pubmed.ncbi.nlm.nih.gov/27721479/
  8. Covarrubias AJ, Perrone R, Grozio A, Verdin E (2021). NAD+ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology. https://pubmed.ncbi.nlm.nih.gov/33353981/

Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.